A safety, tolerability, and pharmacokinetic study of single- and multipleascending doses of LY3473329 in healthy subjects.

Published: 14-07-2020
Last updated: 17-01-2025

The purpose of this study is to investigate how safe the new compound LY3473329 is and how well it is tolerated when it is administered to healthy volunteers. It will also be investigated to determine how quickly and to what extent LY3473329 is...

Ethical review	Approved WMO
Status	Completed
Health condition type	Other condition
Study type	Interventional

Summary

ID

NL-OMON54964

Source
ToetsingOnline

Brief title
SAD/MAD study of LY3473329 in Healthy Subjects.

Condition

- Other condition

Synonym
fat metabolism disorder, Hyperlipidemia

Health condition

Hyperlipidemie

Research involving

Human

Sponsors and support

Primary sponsor: Eli Lilly
Source(s) of monetary or material Support: Farmaceutical Industry.

Intervention

Keyword: Hyperlipidemia, LY3473329

Outcome measures

Primary outcome

Primary (Part A - SAD) To evaluate safety and tolerability of LY3473329 in healthy subjects following a single oral dose

Primary (Part B - MAD) To evaluate safety and tolerability of LY3473329 in otherwise healthy subjects with elevated Lp(a) (>=75 nmol/L or 30 mg/dL) following multiple once-daily oral doses

Secondary outcome

Secondary (Part A - SAD) To evaluate the pharmacokinetics of LY3473329 in healthy subjects following a single oral dose

Secondary (Part B - MAD) To evaluate the pharmacokinetics of LY3473329 in otherwise healthy subjects with elevated Lp(a) (>=75 nmol/L or 30 mg/dL) following multiple once-daily oral doses

Study description

Background summary

In this study, LY3473329 is being researched. This study compound is not registered in the Netherlands as a medication. This means that the study compound is still in development and that it is not known whether the study

compound is safe and if it works. Lipoprotein (a) (Lp[a]) is a substance in the blood that transports cholesterol, fats and proteins. The amount that the body produces is inherited from one or both parents and is genetically determined. Diet and exercise seem to have little or no effect on the Lp(a) level. Elevated levels of Lp(a) are associated with increased risk of cardiovascular disease. LY3473329 is a potential new compound that may decrease major adverse effects in the heart in patients with elevated Lp(a) and cardiovascular disease caused by atherosclerosis.

Study objective

The purpose of this study is to investigate how safe the new compound LY3473329 is and how well it is tolerated when it is administered to healthy volunteers. It will also be investigated to determine how quickly and to what extent LY3473329 is absorbed, distributed, metabolized and eliminated from the body (this is called pharmacokinetics). In addition, the effect of LY3473329 on certain naturally occurring substances present in your blood will be investigated. LY3473329 has not been administered to humans before. It has been previously tested in the laboratory and on animals. The animal studies showed that LY3473329 decreased plasminogen, a protein that may have effects on blood clotting. However, the animals showed no changes to the clotting of their blood.

LY3473329 will be given as oral capsules and will be tested at different dose levels. The effects of LY3473329 will be compared to the effects of a placebo. A placebo is a capsule that does not contain any active compound. Whether the volunteer will receive LY3473329 or placebo will be determined by chance. This study will be performed in up to 113 healthy volunteers. The study will exist of 2 parts, Part A and Part B. The study part in which the volunteer will participate will consist of a maximum of 7 groups of 8 volunteers each. They can participate in one of these groups based on their preference for a specific time period or group.

Study design

The actual study will consist of 1 period during which the volunteers will stay in the research center for 5 days (4 nights). Also, there will be 7 days during which they will visit the research center for a short visit. These short visits will take place on Days 8, 15, 22, 43, 64, 85 and 106 (follow-up).
Day 1 is the day of administration of the study compound. The volunteers are expected at the research center at 14:00 h in the afternoon of Day -1, 1 day prior to the day of administration of the study compound. The entry time can be changed.
They will leave the research center on Day 4 of the study. For the short visits on Days 8, 15, 22, 43, 64, 85 and 106 they are expected at the research center between 12:30 h and 14:30 h in the afternoon. They will be tested for the presence of coronavirus upon entry into the research center.

Intervention

Group A1 on Day 1 LY3473329 1 milligram (mg) or placebo, once
Group A2 on Day 1 LY3473329 10 mg or placebo, once
Group A3 on Day 1 LY3473329 30 mg or placebo once
Group A4 on Day 1 LY3473329 100 mg or placebo, once
Group A5 on Day 1 LY3473329 200 mg or placebo, once
Group A6 on Day 1 LY3473329 400 mg or placebo once
Group A7 on Day 1 LY3473329 800 mg or placebo once

Group B1 on days 1-14 LY3473329 1 milligram (mg) or placebo, once daily
Group B2 on days 1-14 LY3473329 5 mg or placebo once daily
Group B3 on days 1-14 LY3473329 20 mg or placebo once daily
Group B4 on days 1-14 LY3473329 50 mg or placebo once daily
Group B5 on days 1-14 LY3473329 100 mg or placebo once daily

Study burden and risks

Drawing blood and/or insertion of the indwelling cannula may be painful or cause some bruising.
In total, there will be taken about 240 mL of blood. This amount does not cause any problems in adults. To make a heart tracing, electrodes (small, plastic patches) will be pasted at specific locations on the arms, chest and legs. Prolonged use of these electrodes can cause skin irritation (rash and itching).

A sample for the coronavirus test will be taken from the back of the nose and throat using a swab of a sample from the back of the throat may cause the volunteer to gag. When the sample is taken from the back of the nose, they may experience a stinging sensation and the eyes may become watery.

Contacts

Public
Eli Lilly

Arlington Square West 8
Downshire Way Bracknell RG12 1PU
GB
Scientific
Eli Lilly

Arlington Square West 8
Downshire Way Bracknell RG12 1PU
GB

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

1. Healthy male subjects, as determined through medical history and physical examination,
must agree to use a reliable method of birth control
2. Healthy female subjects of child-bearing potential who have a fertile male sexual partner
must be willing and able to practice effective contraception from admission to 105 days
beyond the last dose of study drug. Sexually active subjects must use a combination of 2
of the following methods of contraception, including at least 1 so-called *barrier* method
3. Aged 18 to <55 years, exclusive, at screening.

Exclusion criteria

1. Are currently enrolled in, or discontinued within the past 30 days from, a clinical trial
involving an investigational drug that has not received regulatory approval for any indication,
except for any trial involving antisense Lp(a), for which 6 months must have passed from the
subject*s last study drug dose.
2. Have previously completed or withdrawn from this study or any other study investigating
LY3473329.
3. Are pregnant or breast feeding.

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Completed
Start date (anticipated):	18-08-2020
Enrollment:	113
Type:	Actual

Ethics review

Approved WMO Date:	14-07-2020
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	13-08-2020
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	19-02-2021
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Approved WMO

Date:	26-02-2021
Application type:	Amendment
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2020-002522-91-NL
CCMO	NL74576.056.20

Study results

Date completed:	11-11-2021
Results posted:	18-07-2022

First publication
20-06-2022